Predicting crystallographic B-factors of a protein from a conventional molecular dynamics simulation is challenging in part because the B-factors calculated through sampling the atomic positional fluctuations in a picosecond molecular dynamics simulation are unreliable and the sampling of a longer simulation yields overly large root mean square deviations between calculated and experimental B-factors. This article reports improved B-factor prediction achieved by sampling the atomic positional fluctuations in multiple picosecond molecular dynamics simulations that use uniformly increased atomic masses by 100-fold to increase time resolution. Using the third immunoglobulin-binding domain of protein G, bovine pancreatic trypsin inhibitor, ubiquitin, and lysozyme as model systems, the B-factor root mean square deviations (mean ± standard error) of these proteins were 3.1 ± 0.2-9 ± 1 Å 2 for Cα and 7.3 ± 0.9-9.6 ± 0.2 Å 2 for Cγ, when the sampling was done, for each of these proteins, over 20 distinct, independent, and 50-picosecond high-mass molecular dynamics simulations using AMBER forcefield FF12MC or FF14SB. These results suggest that sampling the atomic positional fluctuations in multiple picosecond high-mass molecular dynamics simulations may be conducive to a priori prediction of crystallographic B-factors of a folded globular protein.
Introduction
The B-factor (also known as the Debye-Waller factor or B-value) of a given atom in a crystal structure is defined as 8π 2 〈u 2 〉 that is used in refining the crystal structure to reflect the displacement u of the atom from its mean position in the crystal structure (viz., the uncertainty of the atomic mean position) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . The displacement u attenuates X-ray scattering and is caused by the thermal motion, conformational disorder, and static lattice disorder of the atom [6] . It is worth noting that the experimentally determined B-factor is not a quantity that is directly observed from an experiment. Instead, it is a function that not only decreases as the resolution of the crystal structure increases [10] but also depends on the restraints that are applied on B-factors in refining the crystal structure [4, 8] . B-factors can be unrealistic if excessive refinement is performed to achieve a higher resolution. B-factors of one crystal structure cannot be compared to those of another without detailed knowledge of the refinement processes for the two comparing structures. It is also worthy of noting that the Subcommittee on Atomic Displacement Parameter Nomenclature recommends avoiding referring to B-factor as "temperature factor" in part because the displacement may not be caused entirely by the thermal motion [7] .
Despite the complex nature of B-factor and challenges of separating the thermal motion in time from the conformational and static lattice disorders in space [11] , B-factors of a protein crystal structure can be used to quantitatively identify less mobile regions of a crystal structure as long as the structure is determined without substantial crystal lattice defects, rigid-body motions, and refinement errors [8, 12, 13] . A low B-factor indicates low thermal motion, while a high B-factor may imply high thermal motion. Normalized main-chain B-factors of a protein have been used as an estimator of flexibility for each residue of the protein [14] [15] [16] [17] [18] [19] to offer useful information for drug-target identification. Unscaled main-chain and side-chain B-factors of a protein can be used to identify ordered regions of a folded globular protein and relatively rigid side chains of active-site residues for target-structure-based drug design [20, 21] . Other uses of B-factors are outlined in Ref. [22] .
As of August 2016, there are more than 65 million protein sequences at the Universal Protein Resource (http://www.uniprot.org/statistics/TrEMBL) compared to about 106 thousand protein crystal structures available at the Protein Data Bank (http://www.rcsb.org/pdb/statistics/holdings.do). This difference indicates that one can use crystallographic methods to determine structures and B-factors of only a fraction of known protein sequences. Most known protein sequences will have to be used for target identification and drug design through generation and refinement of comparative or homology models from the protein sequences [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . Currently, knowledge-based methods can predict main-chain Bfactor distribution of a protein from either its sequence using statistical methods [15, [17] [18] [19] [43] [44] [45] [46] or from its structure using a single-parameter harmonic potential [47, 48] with Pearson correlation coefficients up to 0.71 for the predicted B-factors relative to the experimental values.
These methods do not require intense computation and can rapidly predict B-factors of large numbers of protein sequences to facilitate the use of these sequences in drug-target identification. However, target-structure-based drug design requires more detailed B-factor information than drug-target identification. To design drug candidates whose binding to their protein targets is both enthalpy-and entropy-driven, one needs the information on side-chain motions of active-site residues in a protein target. Prediction of side-chain B-factors by the knowledge-based methods has not been reported to date and may not be feasible through the use of a single-parameter harmonic potential that is inapplicable to high frequency modes pertaining to rapid oscillations of some amino acid side chains [49] .
To complement the current knowledge-based methods, there is a need to develop physicsbased methods for predicting unscaled B-factors of both main-chain and side-chain atoms of a protein crystal structure or a refined comparative protein model from molecular dynamics (MD) simulation. By solving the Newtonian equations of motion for all atoms in a molecular system as a function of time, MD simulation is a general method to simulate atomic motions of the system for insights into dynamical properties of the system such as transport coefficients, timedependent response to perturbations, rheological properties, and spectra [50] . However, predicting B-factors of a folded globular protein by sampling the atomic positional fluctuations of a protein in a conventional MD simulation with solvation may not be feasible because of the use of different protein environments, different timescales to detect thermal motions, and different methods to determine B-factors [51] . For example, a reported MD simulation study showed that the B-factors derived on the picosecond timescale were unreliable and that the simulated Bfactors on the nanosecond timescale were considerably larger than the experimental values [51] .
Although simulations of proteins in their crystalline state [52, 53] can avoid the difference in protein environment, such simulations are inapplicable to a priori B-factor prediction.
This article reports an evaluation study of a physics-based method that samples the atomic positional fluctuations in 20 distinct, independent, unrestricted, unbiased, picosecond, and classical isobaric-isothermal (NPT) MD simulations with uniformly scaled atomic masses to predict a priori main-chain and side-chain B-factors of a folded globular protein for targetstructure-based drug design. The model systems of folded globular proteins used in this study were the third immunoglobulin-binding domain of protein G (GB3; PDB ID: 1IGD; resolution: 1.10 Å) [54] , bovine pancreatic trypsin inhibitor (BPTI; PDB ID: 4PTI; resolution:
1.50 Å) [55] , ubiquitin (PDB ID: 1UBQ; resolution: 1.80 Å) [56] , and lysozyme (PDB ID: 4LZT; resolution: 0.95 Å) [57] . Two distinct AMBER forcefields, FF12MC [42, [58] [59] [60] and FF14SB [61] , were used to evaluate the method in a forcefield-independent manner. The root mean square deviations (RMSDs) and Pearson correlation coefficients (PCCs) between the experimental Bfactors and the predicted values by the physics-based method were compared respectively to the estimated standard error of the experimental B-factors derived from the refinement procedure [8] and to the PCCs of the reported knowledge-based methods [46, 47] in order to assess the quality of the B-factors predicted by the physics-based method. Unless otherwise specified below, all B-factors are unscaled, and all simulations are multiple, distinct, independent, unrestricted, unbiased, and classical NPT MD simulations. kept identical to those of the standard-mass simulation, noting that energy and temperature have the same unit. This is so that the structure and energy of the low-mass simulation system can be compared to those of the standard-mass simulation system. Let superscripts lmt and smt denote the times for the low-mass and standard-mass systems, respectively. theoretically equivalent to standard-mass MD simulations at Δt = fs smt , as long as both standard-mass and low-mass simulations are carried out for the same number of timesteps and there are no precision issues in performing these simulations. This equivalence of mass downscaling and timestep-size upscaling explains why uniform mass reduction can compress the MD simulation time and why low-mass NPT MD simulations at Δt = 1.00 fs smt can offer better configurational sampling efficacy than conventional standard-mass NPT MD simulations at Δt = 1.00 fs smt or Δt = 2.00 fs smt . It also clarifies why the kinetics of the low-mass simulation system can be converted to the kinetics of the standard-mass simulation system simply by scaling the lowmass time with a factor of [60] . Further, this equivalence explains there are limitations on the use of the mass reduction technique to improve configurational sampling efficiency.
Theory
Lengthening the timestep size inevitably reduces integration accuracy of an MD simulation.
However, the integration accuracy reduction caused by a timestep-size increase is temperature dependent. Therefore, to avoid serious integration errors, low-mass NPT MD simulations must be performed with the double-precision floating-point format and at Δt ≤1.00 fs smt and a temperature of ≤340 K [60] . Because temperatures of biological systems rarely exceed 340 K and because MD simulations are performed typically with the double-precision floating-point format, low-mass NPT MD simulation is a viable configurational sampling enhancement technique for protein simulations at a temperature of ≤340 K. In this context, to efficiently sample alternative conformations from a crystallographically determined conformation, low-mass NPT MD simulations at Δt = 1.00 fs smt and temperature of <340 K were used for GB3, BPTI, ubiquitin, and lysozyme in this study.
Using uniformly increased atomic masses to expand the MD simulation time
In the same vein, let superscript hmt denote the time for the system with uniformly increased atomic masses by 100-fold (hereafter referred to as high masses), then at every 50 timesteps of a standard-mass simulation at Δt = 1.00 fs smt [4, 51] rather than sampling conformations saved at every 10 3 timesteps of a high-mass simulation as described in Section 3.2.
However, to simultaneously perform 20 simulations of a large protein with explicit solvation, the high-mass simulations are preferred over the standard-mass simulations because simultaneously saving 20 large files of the coordinates of the protein with a vast number of water molecules at every 50 timesteps is more computationally expensive than at every 10 3 timesteps.
Methods

MD simulations of folded globular proteins
A folded globular protein was solvated with the TIP3P water [63] with surrounding counter ions and then energy-minimized for 100 cycles of steepest-descent minimization followed by 900 cycles of conjugate-gradient minimization to remove close van der Waals contacts using SANDER of AMBER 11 (University of California, San Francisco). The initial conformations of GB3, BPTI, ubiquitin, and lysozyme for the simulations were taken from the crystal structures of PDB IDs of 1IGD, 5PTI, 1UBQ, and 4LZT, respectively. A truncated 1IGD structure (residues 6-61) was used for the GB3 simulations. Four interior water molecules (WAT111, WAT112, WAT113, and WAT122) were included in the initial 5PTI conformation. The simulations for GB3, BPTI, and ubiquitin were done at 297 K as the exact data-collection temperatures of these proteins had not been reported. The lysozyme simulations were done at the reported data-collection temperature of 295 K [57] .
The numbers of TIP3P waters and surrounding ions, initial solvation box size, and protonation states of ionizable residues used for the NPT MD simulations are provided in Table 1 . 
Correlation analysis
PCCs were obtained from correlation analysis using PRISM 5 for Mac OS X of GraphPad Software (La Jolla, California) with the assumption that data were sampled from Gaussian populations.
Results and discussion
Using high-time-resolution picosecond MD simulations to calculate B-factors
The internal motions-such as the motions of backbone N-H bonds of a folded globular protein at the solution state-are on the order of tens or hundreds of ps smt [67] . Therefore, the timescale of the thermal motions reflected in the B-factors of a protein at the crystalline state is unlikely greater than a nanosecond. As described in Section 1, the B-factor of a given atom reflects both the thermal motion and the conformation and static lattice disorders of the atom [6] . In this context, 20 high-mass MD simulations of a folded globular protein were carried out to investigate whether combining the sampling of the atomic positional fluctuations of the protein on a timescale of tens or hundreds of ps smt with the sampling of such fluctuations over conformations derived from the 20 simulations could approximate the experimental B-factors.
High-mass simulations were used to increase the time resolution of the simulations and performed with FF12MChm or FF14SBhm, which denote the AMBER forcefields FF12MC or FF14SB with all atomic masses that were uniformly increased by 100-fold relative to the standard atomic masses.
As listed in Table 2 , regardless of which forcefield was used, the RMSDs between computed and experimental B-factors of Cα and Cγ were <10 Å 2 for all four proteins when the atomic positional fluctuations of these proteins were sampled on the timescale of 50 ps smt . When
FF12MChm was used, longer samplings led to the RMSDs of ≥10 Å 2 for all four proteins, and these RMSDs progressed in time ( Table 2) . When FF14SBhm was used with longer samplings, the RMSDs were also >10 Å 2 for GB3, ubiquitin, and BPTI. For the lysozyme B-factors predicted with FF14SBhm, the RMSDs were <10 Å 2 when the sampling were done on the timescale of <1 ns smt , but the RMSDs were >15 Å 2 for the samplings on the timescale of 10 or 20 ns smt ( and SEs of the B-factor RMSDs of ubiquitin were larger than those of the other proteins (Table   2 ). It was logical to suspect that the conformational variations resulting from 20 simulations might be insufficient to adequately represent the conformational disorder of the ubiquitin crystals. However, increasing the number of the ubiquitin simulations from 20 to 40 or 80 only reduced the SEs but not the means (Table 3) .
For all four proteins, the agreement of the calculated Cα and Cγ B-factors on the timescale of 50 ps smt with the experimental values is shown in Fig. 1, and the SEs of the predicted B-factors shown in Fig. 1 are listed in Table S1 of Supplementary Material. The B-factor RMSDs (mean ± SE) of these proteins using both FF12MChm and FF14SBhm ranged from 3.1 ± 0.2 to 9 ± 1 Å 2 for Cα and from 7.3 ± 0.9 to 9.6 ± 0.2 Å 2 for Cγ (Fig. 1) . The respective PCCs were 0.62-0.87 or 0.63-0.89 for the Cα B-factors of the four proteins that were predicted using FF12MChm or FF14SBhm relative to the experimental B-factors (Fig. 1) . The PCCs of the predicted Cγ Bfactors using FF12MChm or FF14SBhm were 0.41-0.60 or 0.46-0.56 for the four proteins, respectively (Fig. 1) . 
Using multiple distinct initial conformations to improve B-factor prediction
In the above B-factor calculations, the conformational disorders of a protein crystal structure were represented by the conformational variations that resulted from 20 high-mass simulations of a protein. Specifically, each of the 20 simulations used a unique seed number for initial velocities and a common initial conformation that was taken from the protein crystal structure.
These high-mass simulations were performed sequentially for (i) 30 ps smt to set the system temperature to a desired value, (ii) 100 ps smt to equilibrate the system at the desired temperature, Therefore, 20 948-ns smt low-mass MD simulations using FF12MC were carried out for each of the four proteins to obtain protein conformations that differed from the crystallographically determined conformation. FF12MC was used in the low-mass simulations because it could autonomously fold Ac-(AAQAA) 3 -NH 2 [68] , chignolin [69] , and CLN025 [70] in 20 NPT MD simulations 2-6 times faster than FF14SB, suggesting that it has a higher configurational sampling efficiency than FF14SB [42] . In each of the 20 948-ns smt low-mass simulations for each of the four proteins, a unique seed number was used for initial velocities, and the crystallographically determined protein conformation was used as the initial conformation of the 20 low-mass simulations. For each protein, three instantaneous conformations were saved at 316ns smt intervals of each of the 20 low-mass simulations, resulting in three sets of 20 distinct instantaneous conformations saved at 316 ns smt , 632 ns smt , and 948 ns smt . The 20 50-ps smt high-mass
NPT MD simulations using FF12MChm described in Section 4.1 were then repeated three times under the same simulation conditions except that the initial conformations of the 20 highmass simulations were taken from those in one of the three sets of 20 distinct instantaneous conformations that were derived from the 20 low-mass simulations.
As listed in Table 4 , the differences among the B-factor RMSDs derived from using the conformations saved at 316 ns smt , 632 ns smt , and 948 ns smt were marginal. Of these RMSDs, most of the RMSDs on the 50-ps smt timescale are smaller than those on a shorter or longer timescale (Table 4) , which is consistent with the observation described in Section 4.1. For each of the four proteins, there was a significant difference in RMSD between the B-factors derived from using the conformations of the 20 low-mass simulations and those derived from using the respective crystal structure conformation (Table 4 ). For BPTI and lysozyme, the RMSDs derived from the conformations of the low-mass simulations were larger than those from the respective crystal structure, and the difference (mean ± SE) was ≤2.3 ± 0.6 Å 2 (Table 4 ). For GB3 and ubiquitin, the reverse was observed, and the difference (mean ± SE) was ≤2.9 ± 0.6 Å 2 (Table 4 ). These results suggest that use of varied conformations from the crystal structure conformation that are sampled in 20 948-ns smt low-mass simulations may slightly improve the Bfactor prediction for proteins that are devoid of disulfide bonds but slightly impair the prediction for proteins with their conformations restrained by disulfide bonds. [42] .
According to the mass scaling theory for compression or expansion of the MD simulation time described in Section 2, the standard-mass simulation with Δt = 0.10 fs smt is equivalent to the high-mass simulation with Δt = 1.00 fs smt . Indeed, the Cα and Cγ B-factor RMSDs of all four proteins on the 50 ps smt timescale in Table 2 are nearly identical to the corresponding ones in Table S14 of Ref. [42] . Further, the present finding that sampling over 50 ps smt in 20 high-mass MD simulations best reproduces the experimental B-factors is consistent with the report that the internal motions are on the order of tens or hundreds of ps smt [67] . It is also consistent with the report that the experimental Lipari-Szabo order parameters [71] of backbone N-H bonds of the four proteins were best reproduced with NPT MD simulations using FF12MC on the timescale of 50 ps smt [42] . These consistent results suggest that through performing multiple picosecond or ubiquitin [54, 56, 72, 73] . However, the C14-C38 disulfide bond in BPTI flips between left-and right-handed configurations [74] in the NMR structure (PDB ID: 1PIT) [75] . This bond is locked at the right-handed configuration in the crystal structure (PDB ID: 4PTI) [55] . For lysozyme, its C64-C80 disulfide bond adopts both configurations in the NMR structure (PDB ID: 1E8L) [76] and the left-handed configuration in the crystal structure (PDB ID: 4LZT) [57] .
As reported recently in Ref. [42] , sampling the conformation of BPTI in solution using FF12MC Time: the duration of 20 distinct, independent, unrestricted, unbiased, and isobaric-isothermal molecular dynamics simulations over which the B-factors were calculated. RMSD: root mean square deviation. SE: standard error calculated from 20 distinct, independent, unrestricted, unbiased, and isobaric-isothermal molecular dynamics simulations. 
